SEC Company Response from AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702) (FFR) — Apr 7, 2020

AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)
Date: April 7, 2020 · CIK: 0001460702 · Accession: 0001493152-20-005988

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-236235

Date

April 9, 2020

Author

RITTER

Form

CORRESP

Company

AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)

Letter

VIA EDGAR Division of Corporation Finance Attention: Ms. Ada Sarmento and Ms. Celeste Murphy File No. 333-236235 Acceleration Request Requested Date: April 9, 2020 Requested Time: 9:00 A.M. Eastern Time

Re:

Dear Ms. Sarmento and Ms. Murphy:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-4 (File No. 333-236235) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Wendy Grasso and Jennifer Cheng of Reed Smith LLP, counsel to the Company, to make such request on its behalf.

Please confirm the effectiveness of the Registration Statement with Wendy Grasso of Reed Smith LLP by telephone at (917) 993-3645 or, in her absence, Jennifer Cheng of Reed Smith LLP by telephone at (917) 209-5514.

Sincerely,
RITTER
PHARMACEUTICALS, INC.

Show Raw Text

CORRESP
1
filename1.htm

April
7, 2020

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F. Street, NE

Washington,
D.C. 20549

Attention:
Ms. Ada Sarmento and Ms. Celeste Murphy

    Re:

    Ritter
    Pharmaceuticals, Inc.

    Registration
    Statement on Form S-4

    File
    No. 333-236235

    Acceleration
    Request

Requested
Date: April 9, 2020

Requested
Time: 9:00 A.M. Eastern Time

Dear
Ms. Sarmento and Ms. Murphy:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Company”)
hereby respectfully requests that the above-referenced Registration Statement on Form S-4 (File No. 333-236235) (the “Registration
Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth
above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via
telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company
hereby authorizes each of Wendy Grasso and Jennifer Cheng of Reed Smith LLP, counsel to the Company, to make such request on
its behalf.

Please
confirm the effectiveness of the Registration Statement with Wendy Grasso of Reed Smith LLP by telephone at (917) 993-3645 or,
in her absence, Jennifer Cheng of Reed Smith LLP by telephone at (917) 209-5514.

    Sincerely,

    RITTER
    PHARMACEUTICALS, INC.

    /s/
    Andrew Ritter

    Andrew
    Ritter

    Chief
    Executive Officer

cc:
Wendy Grasso and Jennifer Cheng, Reed Smith LLP

SecProbe.io